Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
If approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA decision expected by June 20, 2025.
If approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA decision expected by June 20, 2025.
“Our pharmacy business has never been stronger. We continue to grow and fill the needs of our guests,” Tsipakis says.
By Micah Cost, CEO, Pharmacy Quality Alliance (PQA)
By Sandra Hanna, CEO Neighbourhood Pharmacies.
Ana Archbold is responsible for setting and executing the broader strategy for the company’s Self-Care and Wellness division in the U.S.
The AAM warns that IRA price controls may reduce generics and biosimilars, slowing competition and keeping drug prices high.
The senate vote was split nearly along party lines. Industry organizations respond to confirmation.
Walgreens chief executive Officer Tim Wentworth said on an earnings call last month that the company plans to divest VillageMD and use any proceeds to reduce debt and improve its balance sheet.
According to IQVIA sales data for the 12-month period ending December 2024, the Evoclin Foam, 1% market achieved annual sales of approximately $5.8 million.
For 11 years, the Walgreens Flu Index has provided an early and accurate view of disease trends. The last four consecutive weeks of data have shown increasing flu activity across the U.S.
Findings from a CVS Health analysis show how consumer satisfaction is linked to health-related outcomes.
Each year, more than 40 state pharmacy associations present the award to deserving recipients.
Marks significant expansion of initiative to help health systems access critical, at-risk medications for patients.
New customer offering will enhance insights with medication adherence data.
In collaboration with CPhA and Locumate.
NACDS says “flimsy PBM excuses are dwindling, and for Texans and more Americans help is on the way”.